Patent Exhaustion Doctrine: First Sale and Its Limits
The patent exhaustion doctrine sets a hard boundary on how far a patent holder's exclusive rights extend after an authorized sale of a patented item. Grounded in Title 35 of the United States Code and shaped by Supreme Court precedent, the doctrine determines when a patent owner's control over a product ends and when downstream purchasers gain the freedom to use, resell, or modify what they have lawfully bought. Understanding its mechanics is essential for anyone navigating patent rights and protections, licensing structures, or supply chain transactions involving patented goods.
Definition and scope
Patent exhaustion holds that when a patent holder — or an authorized licensee — makes an unconditional sale of a patented article, the patent rights covering that specific item are "exhausted." The buyer and any subsequent owner take the item free of the patent holder's right to control its further use or resale under patent law.
The doctrine's foundational U.S. Supreme Court statement appears in Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017), where the Court held that exhaustion applies both to domestic authorized sales and to authorized sales made abroad. The Court reasoned that a patent holder who receives the reward of a sale — whether in the United States or overseas — cannot use patent law to impose downstream restrictions on that specific item.
The statutory backdrop is 35 U.S.C. §§ 154 and 271, which together define the exclusive rights of a patent holder (USPTO, 35 U.S.C. § 154). Exhaustion operates as a limitation on those rights rather than as an affirmative grant.
Two structural conditions trigger exhaustion:
- Authorization — the sale must be made by or with the genuine authorization of the patent holder.
- Unconditionality — any restrictions on the sale must be communicated and enforceable through contract, not patent law.
The doctrine is distinct from the patent misuse doctrine, which addresses overreaching licensing conduct more broadly, and from the doctrine of equivalents, which concerns infringement analysis.
How it works
Exhaustion operates through a sequential chain of events:
- Authorized manufacture or import — A patent holder or licensed manufacturer produces a patented article under valid authority derived from the patent grant.
- First authorized sale — The patented item enters commerce through a sale that the patent holder sanctions. This is the triggering event. The price the patent holder receives is treated by courts as the full value extraction permitted under patent law.
- Rights terminate as to that item — Once the authorized sale occurs, the specific article is freed from the patent holder's rights. The buyer may use, resell, repair, or incorporate it into another product without infringing the patent that covers it.
- Downstream transfers — Every subsequent purchaser in the chain inherits the exhaustion benefit. Patent rights do not "re-attach" to the item at any downstream transaction.
A critical operational distinction separates exhaustion from license. A patent holder may attempt to impose post-sale restrictions through a license agreement — for example, a single-use restriction on a patented reagent cartridge. After Impression Products, such restrictions cannot be enforced through patent infringement claims; they may only be pursued as a breach of contract action. This channels the enforcement mechanism from patent courts into ordinary contract doctrine, which carries different remedies and standards.
The interaction between exhaustion and the regulatory context for patent law matters particularly in industries where the USPTO examines method claims alongside product claims. Method patents present a specific complication: the Supreme Court held in Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), that exhaustion can apply to method patents when the authorized sale of a product substantially embodies the patented method and the only reasonable use of the product is to practice that method.
Common scenarios
Authorized domestic sale — standard exhaustion
A manufacturer holds a utility patent on a mechanical component and sells it to a distributor without restriction. The distributor and all downstream buyers are free to resell, use, or incorporate the component. The patent holder cannot sue any of them for infringement based on post-sale conduct.
Conditional sale and contract enforcement
A biotech firm sells patented seed to farmers under a shrink-wrap agreement limiting planting to one generation. In Bowman v. Monsanto Co., 569 U.S. 278 (2013), the Supreme Court held that exhaustion did not protect a farmer who replanted harvested seed because creating a new generation of seeds through planting constitutes making a new infringing article — not merely using the originally purchased item.
International authorized sale
Under Impression Products, an authorized foreign sale exhausts U.S. patent rights for that item. A patent holder cannot block importation of goods it sold abroad. This directly affects pharmaceutical and electronics supply chains where parallel imports move across borders.
Authorized licensee sale
If a licensee's sale falls within the scope of a license grant, that sale exhausts the patent holder's rights just as the patent holder's own sale would. If the licensee sells outside the licensed scope — for example, in a geographic territory not covered by the license — exhaustion does not apply, and downstream purchasers face potential infringement exposure.
Repair versus reconstruction
The exhaustion doctrine permits the repair of an exhausted patented article but not its reconstruction. Reconstruction — essentially manufacturing a new patented article from components — falls outside exhaustion and constitutes infringement. Courts apply a totality-of-circumstances test to distinguish the two, examining factors including the spent nature of the replaced element and the cost of replacement relative to the whole.
Decision boundaries
The following structured breakdown identifies where exhaustion applies and where it does not:
Exhaustion applies when:
- The sale was authorized by the patent holder or a properly authorized licensee
- The sale was unconditional, or conditions were not communicated in a legally enforceable manner
- The downstream activity involves using or reselling the specific authorized item
- A method patent's authorized product sale substantially embodies the patented method (per Quanta)
Exhaustion does not apply when:
- The sale was unauthorized — a theft, a licensee's out-of-scope sale, or a gray-market diversion without authorization
- The downstream user manufactures a new patented article rather than using the purchased one (the Bowman seed-replanting scenario)
- The activity constitutes reconstruction rather than repair
- The patent claim covers a component not present in the sold article — exhaustion is article-specific, not patent-family-wide
Exhaustion versus contract restrictions — the key comparison:
| Enforcement mechanism | Post-sale restriction enforceable? | Remedy available |
|---|---|---|
| Patent infringement | No (post-Impression Products) | None |
| Contract / breach of agreement | Yes, if communicated and binding | Contract damages |
This distinction is operationally significant for parties designing licensing programs around patented consumables. A restriction that cannot survive as a patent claim after an authorized sale may still be enforceable as a contract term, but the choice of forum, available damages, and litigation economics differ substantially.
The exhaustion doctrine also interacts with patent licensing structures in multi-tier supply chains. A patent holder licensing an upstream component supplier must consider whether the downstream OEM's purchase of that component will exhaust rights that the patent holder intended to preserve for a separate license at the OEM level. Courts examine the actual authorization scope communicated at the time of the upstream sale — ambiguity in that authorization tends to resolve against the patent holder under the principle that a restriction the patent holder failed to clearly impose is treated as absent. Reference to the America Invents Act does not alter exhaustion doctrine, which remains rooted in common law and Supreme Court interpretation rather than AIA amendments.
The central resource for the public law of patents remains the U.S. Patent and Trademark Office at uspto.gov, and the full text of Title 35 is maintained at the Office of the Law Revision Counsel. Practitioners and researchers should also consult the full opinions in Impression Products and Quanta, both of which are accessible through the Supreme Court's official opinion archive at supremecourt.gov.